Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.21M | 30.91M | 33.77M | 45.26M | 52.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.21M | 30.91M | 33.77M | 45.26M | 52.30M |
| Cost of Revenue | 94.43M | 96.10M | 97.07M | 102.88M | 109.18M |
| Gross Profit | -69.22M | -65.18M | -63.30M | -57.62M | -56.88M |
| SG&A Expenses | 26.79M | 27.09M | 28.51M | 30.07M | 32.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 121.22M | 123.18M | 125.58M | 132.95M | 141.20M |
| Operating Income | -96.01M | -92.27M | -91.81M | -87.69M | -88.90M |
| Income Before Tax | -87.93M | -90.04M | -90.29M | -83.36M | -83.57M |
| Income Tax Expenses | -58.00K | -1.30M | -3.17M | -5.42M | -5.51M |
| Earnings from Continuing Operations | -87.87 | -88.74 | -87.12 | -77.95 | -78.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.87M | -88.74M | -87.12M | -77.95M | -78.06M |
| EBIT | -96.01M | -92.27M | -91.81M | -87.69M | -88.90M |
| EBITDA | -90.70M | -86.79M | -86.30M | -82.20M | -83.49M |
| EPS Basic | -2.36 | -2.39 | -2.35 | -2.11 | -2.62 |
| Normalized Basic EPS | -1.45 | -1.37 | -1.35 | -1.25 | -1.58 |
| EPS Diluted | -2.36 | -2.39 | -2.35 | -2.11 | -2.62 |
| Normalized Diluted EPS | -1.45 | -1.37 | -1.35 | -1.25 | -1.58 |
| Average Basic Shares Outstanding | 149.00M | 148.83M | 148.25M | 147.72M | 131.84M |
| Average Diluted Shares Outstanding | 149.00M | 148.83M | 148.25M | 147.72M | 131.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |